Vita Life Sciences Limited

ASX:VLS Stock Report

Market Cap: AU$123.8m

Vita Life Sciences Past Earnings Performance

Past criteria checks 2/6

Vita Life Sciences has been growing earnings at an average annual rate of 13.4%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 13.6% per year. Vita Life Sciences's return on equity is 16.8%, and it has net margins of 11%.

Key information

13.42%

Earnings growth rate

12.78%

EPS growth rate

Pharmaceuticals Industry Growth31.22%
Revenue growth rate13.58%
Return on equity16.79%
Net Margin11.05%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Weekly Picks: 💊 VLS' Solvable Headwinds, VOS' Multi-Year Growth, and ISRG's Valuation Concerns

Jun 17
Weekly Picks: 💊 VLS' Solvable Headwinds, VOS' Multi-Year Growth, and ISRG's Valuation Concerns
author-image

Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges

Vita Life Sciences (ASX: VLS) – A Solid Business Seeking Renewed MomentumVita Life Sciences (ASX: VLS) is a well-established healthcare company specializing in the formulation, packaging, distribution

Improved Earnings Required Before Vita Life Sciences Limited (ASX:VLS) Shares Find Their Feet

Feb 21
Improved Earnings Required Before Vita Life Sciences Limited (ASX:VLS) Shares Find Their Feet

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 23
Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Aug 28
Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Mar 22
Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Mar 14
Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 28
Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Dec 20
A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Aug 24
Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

May 14
If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Mar 18
Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Feb 17
Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Jan 20
Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Dec 22
Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Nov 19
Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Jul 14
Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Revenue & Expenses Breakdown

How Vita Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

ASX:VLS Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 24809350
30 Sep 24799340
30 Jun 24799340
31 Mar 24779320
31 Dec 23739300
30 Sep 23718300
30 Jun 23697290
31 Mar 23687290
31 Dec 22677290
30 Sep 22658270
30 Jun 22648260
31 Mar 22618250
31 Dec 21578240
30 Sep 21548230
30 Jun 21507220
31 Mar 21486220
31 Dec 20466210
30 Sep 20466220
30 Jun 20455220
31 Mar 20444230
31 Dec 19423230
30 Sep 19422230
30 Jun 19412230
31 Mar 19412220
31 Dec 18412210
30 Sep 18403210
30 Jun 18404210
31 Mar 18383200
31 Dec 17373200
30 Sep 17373200
30 Jun 17373200
31 Mar 17383200
31 Dec 16383200
30 Sep 16384200
30 Jun 16385200
31 Mar 16395210
31 Dec 15394210
30 Sep 15384200
30 Jun 15374200
31 Mar 15376200
31 Dec 14377190
30 Sep 14367190

Quality Earnings: VLS has high quality earnings.

Growing Profit Margin: VLS's current net profit margins (11%) are lower than last year (12.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: VLS's earnings have grown by 13.4% per year over the past 5 years.

Accelerating Growth: VLS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: VLS had negative earnings growth (-3.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-9.6%).

Return on Equity

High ROE: VLS's Return on Equity (16.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/13 07:47
End of Day Share Price 2025/07/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vita Life Sciences Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aidan BrooksbySelect Equities Pty Ltd
Shane StoreyWilsons Advisory and Stockbroking Ltd.